KOL Perspectives on Rituximab Use in Lupus, 2018 Study - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 25, 2019--The “KOL Perspectives: Rituximab Use in Lupus” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.
In total, we conducted interviews with 10 KOLs -
KOL data is analyzed to produce
Reasons to Buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jv2sw6/kol_perspectives?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190225005397/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/25/2019 05:23 AM/DISC: 02/25/2019 05:23 AM